Source: World journal of surgical oncology [World J Surg Oncol] 2024 Jul 06; Vol. 22 (1), pp. 178. Date of Electronic Publication: 2024 Jul 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection.

Authors : Che Y; Department of Urology, Medical Faculty, University of Duesseldorf, Heinrich- Heine-University, Duesseldorf, Germany. .; Wöltjen C

Subjects: Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/pathology ; Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/surgery ; Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/Neoplasms, Germ Cell and Embryonal*/drug therapy Nonseminomatous germ cell tumor

Source: World journal of surgical oncology [World J Surg Oncol] 2024 Jul 17; Vol. 22 (1), pp. 185. Date of Electronic Publication: 2024 Jul 17.Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Risk factors for residual lesions after total hysterectomy in patients with high-grade cervical intraepithelial neoplasia.

Authors : Wang J; The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, 200030, China.

Subjects: Uterine Cervical Dysplasia*/Uterine Cervical Dysplasia*/Uterine Cervical Dysplasia*/surgery ; Uterine Cervical Dysplasia*/Uterine Cervical Dysplasia*/Uterine Cervical Dysplasia*/pathology ; Hysterectomy*/Hysterectomy*/Hysterectomy*/adverse effects

Source: BMC women's health [BMC Womens Health] 2024 Jun 24; Vol. 24 (1), pp. 369. Date of Electronic Publication: 2024 Jun 24.Publisher: BioMed Central Country of Publication: England NLM ID: 101088690 Publication Model: Electronic Cited Medium: Internet ISSN: 1472-6874

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.

Authors : Aruga Y; Department of Laboratory Medicine, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.; Department of Medical Oncology and Translational Research, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Subjects: Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/pathology ; Neoplasm, Residual*/Neoplasm, Residual*/Neoplasm, Residual*/diagnosis

Source: Scientific reports [Sci Rep] 2024 Jun 11; Vol. 14 (1), pp. 13452. Date of Electronic Publication: 2024 Jun 11.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

Authors : Li EW; Institute of Hematology, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.; Molecular Hematology Laboratory, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia.

Subjects: fms-Like Tyrosine Kinase 3*/fms-Like Tyrosine Kinase 3*/fms-Like Tyrosine Kinase 3*/genetics ; Neoplasm, Residual*/Neoplasm, Residual*/Neoplasm, Residual*/diagnosis ; Neoplasm, Residual*/Neoplasm, Residual*/Neoplasm, Residual*/genetics

Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 26; Vol. 25 (11). Date of Electronic Publication: 2024 May 26.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.

Authors : Yu J; Department of Hematology, Institute of Hematology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.; Luo Y

Subjects: Hematopoietic Stem Cell Transplantation* ; Neoplasm, Residual* ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (10), pp. e7310.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.

Authors : Hermans SJF; Erasmus University Medical Center Cancer Institute, Rotterdam, The Netherlands.; van Norden Y

Subjects: Clofarabine*/Clofarabine*/Clofarabine*/therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*/Precursor Cell Lymphoblastic Leukemia-Lymphoma*/Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*/Precursor Cell Lymphoblastic Leukemia-Lymphoma*/Precursor Cell Lymphoblastic Leukemia-Lymphoma*/mortality

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e6756.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.

Authors : Oh Y; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Department of internal medicine, John H. Stroger Hospital of Cook County, Chicago, Illinois, USA.

Subjects: Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/genetics ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/blood ; Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/Carcinoma, Non-Small-Cell Lung*/pathology

Source: Thoracic cancer [Thorac Cancer] 2024 May; Vol. 15 (13), pp. 1095-1102. Date of Electronic Publication: 2024 Apr 01.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors : Verbeek MWC; Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.; van der Velden VHJ

Subjects: Neoplasm, Residual*/Neoplasm, Residual*/Neoplasm, Residual*/diagnosis ; Flow Cytometry*/Flow Cytometry*/Flow Cytometry*/methods ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis

Source: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 30; Vol. 25 (9). Date of Electronic Publication: 2024 Apr 30.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.

Authors : Chen W; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, China.; Huang J

Subjects: Hematopoietic Stem Cell Transplantation* ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/genetics ; Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/Leukemia, Myeloid, Acute*/therapy

Source: Journal of translational medicine [J Transl Med] 2024 Apr 30; Vol. 22 (1), pp. 410. Date of Electronic Publication: 2024 Apr 30.Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.

Discordance of retroperitoneal and thoracic histologic findings in patients with metastatic germ cell tumors at postchemotherapy residual tumor resection.

Risk factors for residual lesions after total hysterectomy in patients with high-grade cervical intraepithelial neoplasia.

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype.

FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.

Effect of sustained measurable residue disease negativity and post-remission treatment selection on the prognosis of acute lymphoblastic leukemia in adults.

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.

Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.

The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.

Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.

اتصل بنا

اتبع